HBM HOLDINGS-B (02142) announced that its indirect wholly-owned subsidiary, HBM (Shanghai) Co., Ltd., has amended its collaboration, option, and license agreement with AstraZeneca PLC. The revised agreement, effective November 24, 2025, expands the scope of cooperation between the two parties. The enhanced partnership aims to leverage the combined expertise of both companies to jointly discover and develop next-generation biologic therapies, including antibody-drug conjugates (ADCs) and T-cell engagers. The financial terms remain consistent with the framework established under the original agreement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments